NCT06298565View on ClinicalTrials.gov

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

RecruitingOBSERVATIONAL
Enrollment

680

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

June 30, 2034

Study Completion Date

June 30, 2034

Conditions
Myasthenia Gravis
Interventions
BIOLOGICAL

efgartigimod

efgartigimod

Trial Locations (6)

3000

RECRUITING

UZ Leuven (University Hospitals Leuven), Leuven

33487

RECRUITING

SFM Clinical Research, LLC, Boca Raton

33705

RECRUITING

BayCare Health System, Inc. St Anthony's Hospital, St. Petersburg

40241

RECRUITING

Norton Neuroscience Institute, Louisville

62701

RECRUITING

Prairie Education and Research Cooperative and HSHS Medical Group, O'Fallon

78759

RECRUITING

National Neuromuscular Research Institute, Austin

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY

NCT06298565 - A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | Biotech Hunter | Biotech Hunter